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Abstract
Background: The evidence of adherence to statin decreasing risk of major adverse cardiovascular events (MACEs) is
still lack among patients discharged with acute coronary syndrome (ACS).
Our objective is to determine the relationship between six-month adherence to statins and subsequent risk of
MACEs in patients discharged with ACS.
Methods: Using two prospective registry cohorts (CPACS-1 and -2), we analyzed data from 12,516 consecutive patients
with ACS who were prescribed statin at hospital discharge and survived beyond 6 months without recurrent myocardial
infarction (MI) or stroke. Adherence to statin was defined as good (using statin at discharge and 6 months without
declined dosage) and poor adherence groups (using statin at discharge but declining dosage or stopping at 6 months).
We compared the hazard ratios of all-cause mortality and MACE in subsequent 6 months between groups, using Cox-
regression models, adjusting for multiple potential confounders.
Results: Seventy two percent of patients adhered to statin therapy at 6 months. The incident MACE in the poor adherence
group was significantly higher than in good adherence group (2.7% vs. 1.8%, p = 0.002). Compared with poor adherence
group, the good adherence group showed a 27% lower relative risk of MACE during the 6 month follow up (fully-adjusted
hazard ratio (HR) = 0.73; 95%CI: 0.56–0.97). The protective effects of good adherence were similar in groups with different
statin dose as well as groups by other baseline clinical characteristics and treatments (p > 0.05 for interaction).
Conclusion: Our study highlights the importance of adherence to statin therapy in prevention of MACE and clinicians
should aim to achieve higher dosage if tolerable.
Clinical trial registration: CPACS2 was registered on URL: http://www.anzctr.org.au/default.aspx and unique identifier is
ACTRN12609000491268. CPACS1 was not a clinical trial and thus not registered.
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Background
It was estimated that 8.1 million Chinese were affected by
coronary heart disease (CHD) in 2010 [1]. The CHD
events are set to rise with projected increase by 69% be-
tween 2010 and 2030 in China [2]. Acute coronary syn-
drome (ACS) is the most serious presentation of CHD.
Statins are the main stay of treatment in ACS both acutely
and for secondary prevention. Long term use of statins re-
duces the subsequent risk of major adverse cardiovascular
events (MACE) including mortality [3–6] when used in
accordance with international clinical practice guidelines
including Chinese guidelines [7–11].
Despite the strong evidence of protective effect of statins
on subsequent cardiovascular risk, the uptake of statin
therapy in China was modest after ACS; recent studies
have indicated ~80% statin prescription at discharge which
is compounded by subsequent attrition to adherence rates
of less than 60% by 12 months of follow-up [12, 13].
Medication adherence is defined as the extent to which
a patient takes medications as prescribed by their health-
care providers [14]. Poor adherence reduces the effective-
ness of essential medications and has been highlighted as
a significant obstacle in achieving good patient outcomes
[14]. The benefit of adherence to statin on MACE has
been confirmed in the primary prevention of coronary ar-
tery disease among healthy populations [15, 16]. However,
studies on its effects in secondary prevention are still lim-
ited especially in patients discharged with ACS [17–19]. It
is also unknown whether the effects are independent of
good adherence to other evidence-based drugs therapy or
not in these patients. Moreover, in Chinese ACS patients,
about 67.1% did not have known dyslipidaemia [20] and
about 42.8% used low-dose statin (<20 mg atorvastatin or
equivalent) [13]. It is important to quantify the benefit of
statin adherence in Chinese ACS patients with poor ad-
herence, to provide incentive for greater adherence to sta-
tins for secondary prevention.
We therefore set out to determine the relationship be-
tween six-month self-reported adherence to statin use and
subsequent risk of major adverse cardiovascular events
(MACEs) in Chinese patients with acute coronary syndrome
(ACS). We examined the relationship between six-month
adherence to statin post ACS and MACE in the following
6 months among 12,516 ACS patients who had been pre-
scribed to use statin at hospital discharge. We also aimed to
assess if the relationship was independent of good adher-
ence to other evidence-based beneficial drugs, and was con-
sistent in groups with different statin dose as well as groups
by other baseline clinical characteristics and treatments.
Methods
Study population
The study sample was drawn from two multicenter
prospective registry studies of ACS. They are Clinical
Pathways for Acute Coronary Syndromes in China
(CPACS)-1 and-2 which were carried out between 2004
and 2005 and 2007–2009, respectively. The designs and
previous findings of these registries have been reported
elsewhere [12, 20–22]. The two studies designed by the
same study group ensured that data on key variables such
as statin usages (yes/no), death, MI, and stroke were col-
lected with the same methods and definitions, providing
the foundation to merge them for the current study. A
total of 18,038 hospitalised patients with ACS were en-
rolled. These patients were then followed up at 6 and
12 months after discharge. In the present study, we ana-
lyzed 12,516 ACS patients who had been prescribed sta-
tins at discharge, survived to 6 months post-discharge
without recurrent MI or stroke. These patients were then
followed for further 6 months. The study schema is pre-
sented in Fig. 1.
Statin data collection
Data on statin prescription at discharge and at 6 month
after discharge were collected for each patient using
standardized case report forms by trained staff in both
cohorts. The commercial name, and period of using sta-
tin were collected. We defined the “good adherence”
group as those using statin without decline of dosage
between discharge and 6 months post discharge
(n = 9019), and the “poor adherence” group as those
using statin at discharge but with either cessation or
dosage decline at 6 months post discharge (n = 3497).
Dosage of statin was only collected in CPACS-2. In
order to examine the interaction of statin dose on the
relationship of statin adherence with MACE, we per-
formed in subgroups by statin dose (5–10 mg/d and
> = 20 mg/d equivalent dose of atorvastatin) using data
from CPACS-2. For our analysis, the dosage of different
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Fig. 1 Flow chart of study participants
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statins was converted to the equivalent dosage of atorva-
statin according to Chinese Guidelines on Prevention and
Treatment of Dyslipidemia in Adults in 20077 (Additional
file 1: Table S1).
Outcomes ascertainment
Data on outcomes including all-cause mortality, incident
myocardial infarction (including fatal and non-fatal), and
stroke (including fatal and non-fatal) were collected by
two follow-up surveys (by clinic visit or telephone) at 6
and 12 months after discharge [12]. Major adverse car-
diovascular event (MACE) was defined as composite end
point of all-cause mortality, myocardial infarction, or
stroke. All myocardial infarction and stroke events were
diagnosed in hospitals by their physicians. In the present
study, the outcome of interest was MACE occurring
during 7–12 months after discharge and therefore,
deaths, stroke or MI occurring within 6 months after
discharge were excluded from the study.
Other data collection
Other data collected during hospitalization included
sociodemographic characteristics, medical history, fea-
tures of the presenting condition, electrocardiographic
(ECG) and plasma biomarker findings, as well as treat-
ment received at the baseline and during hospitalization.
Other data collected at discharge and 6-month follow-
up included other prescribed medicines (aspirin, clopi-
dogrel, beta-blocker, and angiotensin-converting enzyme
inhibitor/angiotensin receptor blocker), medical history,
presenting features, and diagnosis at discharge. These
variables were analyzed as potential confounders in the
present study.
Statistical analyses
For descriptive purpose, means and standard deviations
were calculated to present continuous variables and were
compared by t-tests between poor and good adherence
groups. Categorical variables were presented as number
(percentage) and differences between groups were tested
by Chi-squared analysis. Cox proportional hazards re-
gression models (unadjusted, age- and sex- adjusted, and
multiple co-variables-adjusted) were constructed to cal-
culate hazard ratios (HR) and corresponding 95% confi-
dence intervals (95%CI) for MACE occurring within 7–
12 month post discharge. The co-variables that were ad-
justed in the models were selected based on the associ-
ation metrics analyses and on the current professional
knowledge. These co-variables included studies (CPACS-
1,-2), subtypes of ACS, hospital level, health insurance,
social economic status, clinical characteristics, concomi-
tant medicines and reperfusion therapies during
hospitalization, and adherence to other evidence-based
secondary prevention treatments for ACS in the first
6 months, in addition to age and sex. All models were
then also constructed for all-cause mortality, incident
MI and stroke, separately.
Subgroup analyses were also performed with the Cox
models in populations defined by age (< or > = 65 years),
sex, type of ACS, presence of hypertension or, diabetes at
baseline, smoking level, hospital type, baseline cardiovascu-
lar risk factors, coronary revascularization during hospital
admission, dose of statin, adherence to other medications.
All p values reported were two sided, and a p value of
< 0.05 was considered significant. All analyses were per-
formed using SAS 9.4 (SAS Institute Inc., Cary, NC, USA).
Results
Baseline characteristics
A total of the 12,516 patients (9019 men and 3497 women)
were eligible to be included in this report (Fig. 1). The
mean age (SD) of the cohort was 63.3 (11.5) years at the
time of hospitalization. The rate of good adherence was
72% (9019/12516) at 6 months after discharge. Compared
with the poor adherence group, the good adherence group
had a higher proportion of men, and were more likely to
have a higher education level, to be treated in tertiary hos-
pital, to have health insurance, to have diabetes mellitus,
dyslipidemia, and taking statins before hospitalization. Dur-
ing hospitalization, the good adherence group were more
likely to have ECG monitoring, and to receive PCI/CABG.
They also were more likely to had good adherence to other
medications at 6 months post discharge, including aspirin,
clopidogrel, beta-blocker, and angiotensin-converting en-
zyme inhibitor/angiotensin receptor blocker (Table 1). The
proportions of participants with 5, 10, 20, and ≥40 mg/d
atorvastatin equivalent dose at discharge were 21, 33, 44,
and 2%, respectively. The dosage levels were significantly
higher in patients who were managed in tertiary hospitals
compared to level-2 hospitals (p < 0.001)(Fig. 2).
Adherence to statin and MACE
Among 12,516 patients with event-free survival to 6 months
follow up, a total of 259 MACE occurred during the subse-
quent 6 months. The crude incidence rate of MACE events
was statistically significantly lower in the good adherence
group compared to the poor adherence group. After adjust-
ment for co-variables, the association was attenuated, but
remained statistically significant (Table 2).
Adherence to statin and components of MACEs
There were a total of 146, 96 and 49 patients resulted in
death, myocardial infarction and stroke during follow up.
The crude incidence rate of almost components of MACE
was statistically significantly lower in the good adherence
group compared to the poor adherence group, but after
adjustment for co-variables, the associations were attenu-
ated and not statistically significant (Table 2).
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Sub-group analyses
All associations of adherence to statin with MACE were
consistent between study cohorts and pre-defined sub-
groups of baseline characteristics including the sub-types of
ACS (Fig. 3). There were not significant interactions be-
tween adherence to statin and other main exposure factors.
Discussion
Our results demonstrate that good adherence to statin
in the first 6 months after discharge is associated with
subsequent lower incidence of MACE (including all-
cause mortality, MI, and stroke) in a large unselected
Chinese ACS patient population. This relationship was
Table 1 Baseline clinical characteristics according to the statin use adherence at six months after discharge
Baseline variables Good adherence Poor adherence P-value
(n = 9019) (n = 3497)
Studies, n(%)
CPACS-1 1415(15.7) 512(14.6) 0.145
CPACS-2 7604(84.3) 2985(85.4)
Male, n(%) 6380(70.7) 2390(68.3) 0.009
Age,mean(SD) 63.33(11.5) 63.34(11.8) 0.974
High School or higher, n(%) 3444(38.2) 1252(35.8) 0.013
Occupations, n(%)
Employed 4605(51.1) 1767(50.5) 0.844
Not-employed 4214(46.7) 1654(47.3)
Unknown 200(2.2) 76(2.2)
Tertiary hospital, n(%) 5781(64.1) 1987(56.8) <0.001
Having health insurance, n(%) 7308(81.0) 2700(77.2) <0.001
Smoking, n(%) 2748(30.5) 1096(31.3) 0.343
Subtype of ACS, n(%)
STEMI 3530(39.1) 1347(38.5) 0.104
Non-STEMI 1206(13.4) 427(12.2)
Unstable angina 4283(47.5) 1723(49.3)
CVD risk factors, n(%)
Hypertension 6354(70.5) 2402(68.7) 0.053
Diabetes Mellitus 1892(21.0) 655(18.7) 0.005
Dyslipidemia* 4807(53.3) 1734(49.6) <0.001
Smoking 2748(30.5) 1096(31.3) 0.343
Obesity 897(10.0) 321(9.2) 0.194
Family history of early CHD, n(%) 414(4.6) 171(4.9) 0.476
Higher heart rate(> = 100/min),n(%) 657(7.3) 277(7.9) 0.224
Continuous ECG monitoring, n(%) 6487(71.9) 2436(69.7) 0.012
Treatments during hospitalization, n(%)
PCI/CABG 4746(52.6) 1334(38.2) <0.001
Thrombolysis 608(6.7) 318(9.1) <0.001
Statin before hospitalization 1681(18.6) 513(14.7) <0.001
PCI/CABG in 0–6 months, n(%) 308(3.4) 131(3.8) 0.3663
Adherence of other medications in 0–6 months, n(%)
Aspirin 8573(95.1) 2742(78.4) <0.001
Clopidogrel 5962(66.1) 1414(40.4) <0.001
Beta-blocker 6602(73.2) 1772(50.7) <0.001
Angiotensin-converting enzyme inhibitor/Angiotensin receptor blocker 6312(70.0) 1493(42.7) <0.001
*Dyslipidemia was defined as having a history of dyslipidemia or total serum cholesterol>=240mg/dL, or LDL-c>=160mg/dL, or triglyceride>=200mg/dL,
or HDL-c<40mg/dL according to the guideline of China
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independent of other treatments which have been
shown to be associated with outcomes in ACS such as
receipt of coronary interventions, and adherence to
antiplatelets, aspirin, beta-blocker, and angiotensin-
converting enzyme inhibitor/angiotensin receptor
blocker, as well as other known personal prognostic fac-
tors such as age, sex, education level, and cardiovascular
risk factors and other hospital level characteristics. In
addition, the effect of adherence was not modified by
the characteristics of patients such as dose of statins,
subtypes of ACS, gender, age, social economic status,
etc.
It has been well established that good statin adherence
is associated with reduced the risk of MACE and all-
cause mortality in the primary prevention of coronary
artery disease among healthy populations [15, 16]. The
benefits associated with statin adherence in secondary
prevention have only been reported among elderly AMI
Fig. 2 The proportion of patients prescribed different statin dosage in tertiary hospitals and level 2 hospitals (p < 0.001)






Unadjusted Age-sex-adjusted Fully-adjusted a
MACE Poor adherence 95(2.72) 1(ref.) 1(ref.) 1(ref.)
Good adherence 164(1.82) 0.66(0.51,0.85) 0.68(0.52,0.87) 0.73(0.56,0.97)
P values 0.002 0.001 0.002 0.030
Total death Poor adherence 56(1.60) 1(ref.) 1(ref.) 1(ref.)
Good adherence 90(1.00) 0.62(0.44,0.86) 0.63(0.45,0.88) 0.71(0.49,1.04)
P values 0.005 0.005 0.007 0.077
MI Poor adherence 30(0.86) 1(ref.) 1(ref.) 1(ref.)
Good adherence 66(0.73) 0.84(0.55,1.3) 0.85(0.55,1.3) 0.88(0.55,1.41)
P values 0.468 0.444 0.447 0.6
Stroke Poor adherence 21(0.60) 1(ref.) 1(ref.) 1(ref.)
Good adherence 28(0.31) 0.51(0.29,0.9) 0.53(0.3,0.93) 0.56(0.3,1.02)
P values 0.020 0.02 0.026 0.059
aAdjusted for studies (CPACS-1,-2), age, sex, education, occupations, have health insurance, hospital level, cardiovascular risk factors (hypertension, diabetes,
dyslipidemia, obesity, smoking, and family history of early CHD), higher heart rate(> = 100/min), continuous ECG monitoring, subtype of ACS, thrombolysis, statin
before hospitalization, PCI/CABG during hospitalization, PCI/CABG from 0- to 6- month after discharge, and adherence to clopidogrel, aspirin, beta-blocker,
and ACEI/ARB
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survivors for more than 1 year and three months18 and
in known CVD (angina, myocardial infarction, heart fail-
ure, stroke/transient ischaemic attack and peripheral
vascular disease as a whole) patients [19]. Such evidence
among patients discharged with ACS is lacking and to
the best of our knowledge, the present study is the first
one to show good adherence to statin therapy during the
first 6 months after discharge was significantly associ-
ated with lower risk of MACE in subsequent 6 months
among ACS patients. Moreover, we found the relation-
ship was not modified by statin dose, subtype of ACS,
PCI/CABG, dyslipidemia, other clinical characteristics,
and demographics, and was independent of good adher-
ence to other evidence-based beneficial drugs, including
antiplatelets, beta-blocker, and angiotensin-converting
enzyme inhibitor/angiotensin receptor blocker at same
time. Our findings suggest that adherence to statin is
beneficial even in those ACS among whom about 50%
did not have dyslipidemia and 54% had lower statin dose
(<20 mg atorvastatin or equivalent).
Our findings highlight the importance to improve
adherence to statin in the secondary prevention
among ACS patients among Asian populations. We
note that the level of good adherence to statin rate
was only 72% at the 6 months after discharge in our
study; considering the expected even lower adherence
at 12 months as shown in CPACS-1 study [12], it was
substantially lower than the adherence reported in
Canadians [18]. Therefore, there is clearly room for
improvement and ensuring good adherence to statins
may translate into substantial clinical benefit with
regard to MACE.
Our findings for each of the MACE components
showed that the hazard ratio for patients with good ad-
herence vs poor adherence was all less than 1.0 and bor-
derline significant. We consider the results are coherent
with the significant findings for the primary study out-
come. Our ad-hoc power analysis indicated that the
study power is 87% to detect the observed effect size on
the primary outcome, MACE, 78% on total death, 13%
on MI and 63% on stroke, with a = 0.05 among 12,500
study participants.
Strengths
The participants were drawn from CPACS1 and CPACS2
which were well designed studies with high scientific qual-
ity standards [12, 20–22]. Firstly, we assessed the relation-
ship of adherence to statin at 6 months after discharge
with subsequent clinical outcomes during 7–12 months
after excluding those patients with MI or stroke events in
the first 6 months. This approach would avoid bias to-
wards a result unfavorable to good adherence because the
patients with recurrence of MI/stroke during the first
6 months were more likely to take statin at 6 month and
hence be defined as adhere to statin in our study. Sec-
ondly, we controlled all available potential confounders in-
cluding studies(CPACS-1,-2), age, sex, health insurance,
social economic status, clinical characteristics, use statin
before hospital, concomitant medicines and reperfusion
therapies during hospitalization, and adherence to other
Fig. 3 Hazard ratios of major adverse cardiovascular events (MACEs) for patients with good adherence compared to patients with poor adherence by
cohorts (CPACS-1 and -2) and baseline characteristics. HRs were estimated with Cox model with adjustment for all other covariables shown in the fig.
PCI = percutaneous coronary intervention. CABG = coronary artery bypass graft. ACEI = angiotensin converter enzyme inhibitor. ARB = angiotensin
receptor blocker
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evidence-based secondary prevention treatments for ACS
in the first 6 months.
Limitations
There are some limitations. First, we only defined good
adherence as using statin without dosage reduction at
6 months, and poor adherence as using statin at dis-
charge but dosage declined or discontinued usage at
6 months. Compared with common definition using the
proportion of days covered (PDC) > =80% as good ad-
herence, and 40–79%as poor adherence [23], we possibly
misclassified some patients and thus under-estimated
the strength of the associations observed. Second, as an
observational study, we cannot assert causality due to
the unmeasured and unknown confounding factors.
Third, our data on adherence was self-reported, though
a sample of study participants were randomly selected
and central calls were made to confirm the quality of fol-
low up data. Fourth, there was no independent adjudica-
tions of events in our study which make the diagnoses of
MI/stroke might not be accurate. Finally, we only
assessed the adherence at a single time point at relatively
short interval of six-month post-discharge. Compared
with longer-term adherence, the short-term adherence
may have smaller magnitude of benefit as statins benefit
has been more commonly acknowledged over at least
12–18 month therapy.
Conclusion
In summary, this study found that ACS patients with
good adherence to statin in the first 6 months after dis-
charge had significantly lower risk of subsequent MACE
in the following 7 to 12 months. Our study highlights
the importance of adherence to cholesterol lowering
therapy in prevention of MACE. Whilst the results are
broadly similar to previous reports in Western popula-
tions, our study provide strong incentive with regard to
relevance of statin adherence in reduction in MACE in
the Chinese ACS patients.
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